In early January 2021, it was announced that North Carolina based Chimerix (Nasdaq: CMRX) had acquired the privately-held biotech company Oncoceutics Inc that since 2009 has been structured around utiizing emerging therapies to combat cancer. A clinical-stage biopharmaceutical company, Oncoceutics has been engaged in the discovery and development of highly differentiated treatments for difficult cancers. The lead canfidate for is ONC201, an oral, small-molecule drug that acts against numerous tumor types by sparing healthy cells and targeting the most potent tumor suppressor pathways. The related clinical trials has involved the young, small firm with leading cancer centers tp include Massachusetts General Hospital, Rutgers Cancer Institute of New Jersey, Fox Chase Cancer Center and - via a landmark alliance - University of Texas MD Anderson Cancer Center. Oncoceuticsâ pipeline includes ONC201 in multiple trials at various stages, and several analogs with improved and differentiated profiles in preclinical testing. Focused on safely and durably prolonging the lives of cancer patients, the effort is on development a novel class of targeted, apoptosis-inducing cancer treatments that avoid toxicity, possess broad anti-tumor activity, and overcome mechanisms of drug resistance
